Search research articles
Contact Us
Filters
Showing results (201-210 of 220) with videos related to
Page
of 22
Sort By:
European Journal of Neurology
|
October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease
M Horstink, E Tolosa, U Bonuccelli, et al.
Revue Neurologique
|
June 22, 2021
Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation
B Fernández-Rodríguez, J Dupouy, E Harroch, et al.
European Journal of Neurology
|
October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease
M Horstink, E Tolosa, U Bonuccelli, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 1, 1988
Is adrenal medulla involved in the antihypertensive effect of nicardipine?
M A Tran, G De Saint-Blanquat, P Valet, et al.
Annals of Neurology
|
June 9, 1999
ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease
O Rascol, O Blin, C Thalamas, et al.
Revue Neurologique
|
June 12, 2012
Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL)
W G Meissner, A Foubert-Samier, S Dupouy, et al.
Parkinsonism & Related Disorders
|
May 26, 2020
Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study
J Ihle, F Artaud, S Bekadar, et al.
Neurology
|
September 30, 2010
Motor activation in multiple system atrophy and Parkinson disease: a PET study
P Payoux, C Brefel-Courbon, F Ory-Magne, et al.
Parkinsonism & Related Disorders
|
August 3, 2015
Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program
P Odin, K Ray Chaudhuri, J T Slevin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
August 2, 2001
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
O Rascol, I Arnulf, H Peyro-Saint Paul, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 220) with videos related to
Sort By:
Page
of 22
European Journal of Neurology
|
October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease
M Horstink, E Tolosa, U Bonuccelli, et al.
Revue Neurologique
|
June 22, 2021
Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation
B Fernández-Rodríguez, J Dupouy, E Harroch, et al.
European Journal of Neurology
|
October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease
M Horstink, E Tolosa, U Bonuccelli, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 1, 1988
Is adrenal medulla involved in the antihypertensive effect of nicardipine?
M A Tran, G De Saint-Blanquat, P Valet, et al.
Annals of Neurology
|
June 9, 1999
ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease
O Rascol, O Blin, C Thalamas, et al.
Revue Neurologique
|
June 12, 2012
Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL)
W G Meissner, A Foubert-Samier, S Dupouy, et al.
Parkinsonism & Related Disorders
|
May 26, 2020
Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study
J Ihle, F Artaud, S Bekadar, et al.
Neurology
|
September 30, 2010
Motor activation in multiple system atrophy and Parkinson disease: a PET study
P Payoux, C Brefel-Courbon, F Ory-Magne, et al.
Parkinsonism & Related Disorders
|
August 3, 2015
Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program
P Odin, K Ray Chaudhuri, J T Slevin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
August 2, 2001
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
O Rascol, I Arnulf, H Peyro-Saint Paul, et al.
Page
of 22